Combining it with Tempol, it develops a novel therapeutic, with SCD therapeutic activity as effective as EAF P3K6 Hb (an oxygen therapeutic) in attenuating the mild disease pathology of NY1DD mice. Here, GSTM1 is linked to Schnyder corneal dystrophy.